fda import alert green list glp-1 semaglutide tirzepatide 2025 September 8, 2025: launches an listing safe manufacturers – Partnership for Safe Medicines For more information please visit

However, its future trajectory is far from linear as many uncertainties remain, e.g., acceptance of obesity as a chronic disease, budget impact faced by payers and health systems willingness and ability to pay, the readout of further cardiovascular outcomes trials after the high profile results of 2023s SELECT trial for Wegovy, or new entrants challenging first generation therapies with alternative mechanisms of action (MoA) to address shortcomings such as gastrointestinal tolerability, current drugs being injectables, or the durability and quality of weight loss which distinguishes between fat and lean body mass

adults having tried...

Learn key insights from Springbuk's 2024 Employee Health Trends update on managing expenses while prioritizing employee well-being.

This category includes compounds such as semaglutide, tirzepatide, and retatrutide, each handled under structured sourcing and verification protocols

Weight loss injections seem to be more popular, but "compounded" versions of these drugs can vary in how people access them.

Sulfur burps are a common side effect of GLP-1 medications like semaglutide, caused by slower gastric emptying and bacterial fermentation in the digestive tract